Forvis Mazars Wealth Advisors LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forvis Mazars Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,255 shares of the biopharmaceutical company’s stock after purchasing an additional 41 shares during the quarter. Forvis Mazars Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,319,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $37,000. Private Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 0.6 %

REGN opened at $700.33 on Monday. The firm has a market capitalization of $76.56 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08. The firm’s 50 day moving average is $699.40 and its 200-day moving average is $881.17. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Bank of America reiterated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.